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Abstract: It is increasingly recognized that large proportions of patients with asthma remain 
poorly controlled with daily symptoms, limitation in activities, or severe exacerbations despite 
traditional treatment with inhaled corticosteroids and other agents. This suggests that there is 
considerable scope for the refinement of traditional guidelines on the use of inhaled therapies 
in asthma and also a need for the development of novel therapeutic agents, particularly for the 
treatment of severe asthma. This review aims to discuss a range of emerging treatment approaches 
in asthma. Firstly, we will set the scene by highlighting the importance of achieving good 
asthma control in a patient-focused manner and discussing recent work that has furthered our 
  understanding of asthma phenotypes and paved the way for patient-specific treatments. Secondly, 
we will review new strategies to better use the existing therapies such as inhaled   corticosteroids 
and long-acting β2-agonists that remain the mainstay of treatment for most patients. Finally, 
we will review the novel therapies that are becoming available, both pharmacological and 
  interventional, and discuss their likely place in the management of this complex disease.
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Introduction
Asthma is largely regarded as a chronic inflammatory respiratory disease   manifesting 
in variable airflow obstruction and symptoms of cough, wheeze, and dyspnea. 
This   definition continues to undergo refinement in concert with developments in 
pathophysiology, immunology, and pharmacology.1 The infiltration of airway tissues 
with increased numbers of eosinophils, a hallmark of allergic disease, is also seen 
in asthma.2 Although debate continues as to the role of these inflammatory cells in 
mediating the expression of asthma, little doubt remains to the long-known efficacy of 
glucocorticoids in reducing both the blood and airway eosinophilia with consequent 
improvements in symptoms and lung function,3,4 and an attenuation in its decline.5
Most patients with asthma achieve good disease control with principal use of 
inhaled corticosteroids and long-acting β2-adrenoceptor agonists (LABAs) that are the 
mainstay of asthma therapy. These therapies, however, unfortunately fail to afford a 
significant proportion of patients with good control of their symptoms or prevent severe 
exacerbations.
There are a number of possible reasons for this limitation in the efficacy of tradi-
tional therapies, including 1) a failure of traditional guidelines to reflect patients’ own 
priorities of asthma control; 2) inappropriate timing of the introduction of   treatments 
or the use of inadequate doses; 3) a poor understanding of different asthma   subgroups, 
which due to their distinct  pathophysiology have different pharmacological responses;   Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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4) limitations in the ability of patients to adhere to prescribed 
regimens; and 5) a proportion of patients genuinely having 
severe disease who are resistant to treatment (difficult-to-
treat asthma). This review will outline a number of strategies 
that are now recommended to address these limitations in 
asthma management. We will highlight the important goals 
in asthma management, offer definitions of difficult-to-treat 
asthma, and present the background to the development of our 
understanding of asthma phenotypes before reviewing specific 
management strategies and novel therapeutic options.
Importance of asthma control  
and preventing exacerbations
The goal of achieving good asthma control has become 
increasingly important with the recognition of its   increasing 
prevalence in the general population.6 Given that not 
all emergency visits for asthma or exacerbations can be 
avoided, they represent a high cost in terms of a poorer 
quality of life, days off work or school, and the consequent 
financial loss while poor symptom control invariably 
gives rise to increased health care utilization. Emergency 
hospital admissions, for example, are significantly costly, 
accounting for £61 million of the estimated £1 billion cost 
of asthma to the NHS each year in the UK.7 In addition, 
although severe asthma accounts for ,5% of asthma in the 
general population, it consumes a disproportionate share 
of resources,8 with associated health care   expenditures 
in severe asthma being more than 6 times those of mild 
  asthma.9 That said, it is increasingly recognized that 
although severe   exacerbations and hospital admissions 
represent the extreme of asthma morbidity, many patients 
with relatively mild asthma   continue to experience 
  unacceptable levels of daily symptoms, which significantly 
impacts their day-to-day activities and health status.10,11 
Consequently, current asthma treatment guidelines (BTS/
SIGN 2009,12 ATS/ERS joints statement,13 and GINA14) 
have been updated to highlight the importance of   adjusting 
asthma therapy with the aim of attempting to prevent 
severe exacerbations and admissions while also   minimizing 
daily symptoms and maximizing quality of life. They also 
  recognize the importance of considering the likelihood of 
future deteriorations in asthma control when reviewing 
treatment regimens for individual patients.15
Difficult-to-treat asthma
Severe asthma represents an extreme in the spectrum of the 
asthma population in those (5%–10%) who despite a period 
of extensive re-evaluation of diagnosis and management 
  cannot be controlled with a combination of high-dose inhaled 
corticosteroids together with LABAs.
Although no universally agreed definition exists, various 
labels, such as refractory asthma (Table 1),16 severe asthma, 
and therapy-resistant asthma, have all been ascribed to 
this aspect of asthma. Difficult-to-treat asthma may be 
characterized by poor symptom control, persistent airflow 
obstruction, and/or recurrent exacerbations, including fatal 
or near-fatal episodes, despite high medication require-
ments to maintain disease control, which itself too often 
complicates the   illness.16 The concept of difficult-to-treat 
asthma is highlighted here because this group of patients is 
likely to be the group for which novel approaches, includ-
ing specific   targeted therapies, are likely to be particularly 
needed. In these patients, existing therapies either do not 
achieve adequate control or do so only at high doses, leading 
to unacceptable side effects. The lack of a consistent defini-
tion and the wide range of clinical presentations reflect the 
Table  1  Refractory  asthma:  workshop  consensus  for  typical 
clinical features*
Major characteristics
in order to achieve control to a level of mild to moderate persistent asthma:
1.   Treatment with continuous or near-continuous (50% of year) oral 
corticosteroids
2. Requirement for treatment with high-dose inhaled corticosteroids
  Drug Dose (µg/d) Dose (puffs/d)
  a.   Beclomethasone 
dipropionate
.1260 .40 puffs  
(42 µg/inhalation)
.20 puffs  
(84 µg/inhalation)
  b. Budesonide .1200 .6 puffs
  c. Flunisolide .2000 .8 puffs
  d. Fluticasone propionate .880 .8 puffs (110 µg),  
.4 puffs (220 µg)
  e. Triamcinolone acetonide .2000 .20 puffs
Minor characteristics
1.   Requirement for daily treatment with a controller medication 
in addition to inhaled corticosteroids, eg, long-acting β-agonist, 
theophylline, or leukotriene antagonist
2.   Asthma symptoms requiring short-acting β-agonist use on a daily  
or near-daily basis
3.   Persistent airway obstruction (Fev1 ,80% predicted; diurnal PeF 
variability .20%)
4. One or more urgent care visits for asthma per year
5. Three or more oral steroid ‘bursts’ per year
6.   Prompt deterioration with 25% reduction in oral or inhaled 
corticosteroid dose
7. Near-fatal asthma event in the past
Note:  *Requires  that  other  conditions  have  been  excluded,  exacerbating  factors 
treated, and patient felt to be generally adherent. 
Definition  of  refractory  asthma  requires  one  or  both  major  criteria  and  two 
minor criteria. Copyright © 2010, American Thoracic Society. Reproduced with 
permission from Proceedings of the ATS workshop on refractory asthma: current 
understanding,  recommendations,  and  unanswered  questions. American Thoracic 
Society. Am J Respir Crit Care Med. 2000;162(6):2341–2351.Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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heterogeneous nature of asthma in general17,18 and difficult-
to-treat asthma in particular.1,2 A sound understanding of this 
heterogeneity is crucial for the successful development and 
appropriate utilization of new therapies for difficult-to-treat 
asthma and will now be discussed (see Table 1).
Asthma heterogeneity and phenotyping
Characterizing patients with asthma offers particular benefits 
in treating moderate to severe asthma providing not only prog-
nostic information but also targeted therapeutic opportunities 
and helping to formulate a tailored approach to management. 
Historically, various methods of characterizing the heterogene-
ity of asthma have been considered based on specific features 
such as the age of onset, nature of airflow obstruction, pattern 
of exacerbations, or inflammatory profile.1,17,19 These systems 
of asthma classification are limited by inconsistency of method, 
subjective bias, and a failure to address the multiple dimensions 
of the disease, leading to models of little clinical significance. 
These limitations have led to increasing interest in more care-
ful attempts at classification using multidimensional analytical 
techniques to identify specific asthma phenotypes.
We have recently described the results of a study using the 
technique of cluster analysis within a population of patients 
with severe asthma treated in our clinic compared with a   second 
population managed in primary care.   Cluster   analysis is a 
multivariate statistical tool that seeks to organize   information 
about variables so that heterogeneous groups of subjects can 
be classified into relatively homogeneous subgroups or ‘clus-
ters’. By including large numbers of   variables, this approach 
may reveal associations that were not   previously evident 
and lead to the   identification of   distinct novel   phenotypes. 
Our results (Figure 1)   identified two clusters (early-onset 
atopic asthma and obese, noneosinophilic asthma) that were 
  common to both asthma   populations. In contrast, two clus-
ters characterized by marked   discordance between symptom 
expression and eosinophilic airway inflammation (early-onset, 
symptom-predominant asthma and   late-onset, inflammation-
predominant asthma) were   specific to   refractory asthma. The 
identification of these separate phenotypes of asthma and in 
particular the recognition of the disparity between symptoms 
and inflammation highlight the need for the development 
of different management strategies for different groups of 
patients. A management strategy based on targeting airway 
inflammation may be particularly helpful for patients with 
inflammation-predominant asthma,15 for example, and will 
be discussed later. Further consideration of the complexity of 
the different aspects of airways disease has led to the recent 
suggestion that traditional labels applied to airways disease 
Discordant
symptoms
Discordant
inflammation
Concordant
disease
Primary care asthma
Eosinophilic inflammation
Symptoms
Secondary care asthma
EARLY SYMPTOM
PREDOMINANT
Early onset, atopic,
normal BMI,
high symptom expression
OBESE
NONEOSINOPHILIC
Later onset, female preponderance,
high symptom expression
BENIGN ASTHMA
Mixed middle-aged cohort,
well-controlled symptoms and
inflammation, benign prognosis
INFLAMMATION PREDOMINANT
Late onset, greater proportion of males,
few daily symptoms but active eosinophilic
inflammation
EARLY-ONSET
ATOPIC ASTHMA
Concordant symptoms, inflammation, and airway
dysfunction
Monitoring inflammation
allows downtitration of
corticosteroids.
A symptom-based approach to
therapy titration may be
sufficient
Monitoring inflammation allows
targeted corticosteroids to lower
exacerbation frequency
Figure 1 Clinical asthma phenotypes. Copyright © 2010, American Thoracic Society. Reproduced with permission from Haldar P, Pavord iD, Shaw De, et al. Cluster analysis 
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(including asthma and chronic obstructive   pulmonary disease 
[COPD]) be replaced by an A to E   alphabetical assessment 
tool using factors potentially responsible for   morbidity: 
airway hyperresponsiveness, bronchitis, cough reflex 
hypersensitivity, and damage to the airway and   surrounding 
lung, and extrapulmonary factors.20 This may offer a useful 
checklist to remind the clinician of the need to relate clinical 
presentation with underlying pathophysiology, and in doing 
so to select the most appropriate treatment strategy. For some 
patients, particularly those with difficult-to-treat asthma, this 
may be a novel pharmacological agent, whereas, for others, 
more judicious use of existing treatments may be sufficient 
to achieve good control.
Improving the use of existing 
asthma therapies: patient-focused 
management strategies
Self-management plans
Patients with asthma deserve both oral and written advice 
helping them to recognize the signs of asthma and what to 
do when it is worsening.
With this in mind, one of the most significant advances 
in patient-focused developments in asthma therapy has 
been the way medications are employed. In particular, 
and in common with most chronic diseases, empower-
ing patients to take responsibility through education is 
considered to be necessary to help patients gain the skills 
and confidence to control their asthma. A practical way of 
doing this is to provide patients with a written asthma self-
management or ‘action’ plan, an example of which is given 
in Table 2. This has seen distinct benefits both in economic 
terms and in reductions in   morbidity in a recent Cochrane   
review.21
It is well recognized that patients frequently fail to fully 
appreciate the severity of their asthma symptoms.22 Prior 
to most exacerbations is a period of deteriorating control 
usually seen 10–3 days prior to a more significant decline 
in symptom control.23 This pattern of escaping asthma 
control underwrites the utility of self-management plans, 
which, although based on an objective test such as peak 
flow measurements, often parallel a decline with symptoms 
of increasing wheeze and dyspnea. It allows patients, in 
particular those with concordant airway inflammation and 
symptoms, the prospect of recognizing escaping control 
and initiating early treatment with inhaled corticosteroids, 
rapidly suppressing airway inflammation that occurs during 
the evolution of an exacerbation, preventing its development, 
and thereby reducing mortality and morbidity by preventing 
hospital admissions.24
There is, however, a substantial variation in the structure 
and implementation of self-management plans,25 and factors 
facilitating their long-term use are not fully understood.26
Stepwise incremental management
Traditionally, inhaled therapies have been used in a symptom-
guided strategy, which remains the most widely accepted and 
practised strategy in optimizing asthma control. Although 
inhaled corticosteroids27 have been shown to be arguably 
the most important therapeutic and beneficial intervention 
in patients with airway disease, the importance of LABAs 
cannot be understated.
The Gaining Optimal Asthma Control (GOAL)10 study, 
one of the largest studies utilizing both combination and 
separate therapies, explored the potential of achieving total 
control of asthma symptoms. In this study, treatment was 
optimized in those with uncontrolled asthma symptoms, by 
increasing combination therapy at three monthly reviews 
until all asthma-related symptoms were abolished based on 
widely accepted guidelines.
Reconfirming earlier findings from similar trials of 
the importance of LABAs,28 it demonstrated that good 
control was achieved more rapidly by this strategy and 
at a lower corticosteroid dose with the fixed-dose inhaled 
corticosteroid and LABA combination product (seretide) 
than fluticasone alone despite total control not being 
achieved in the majority of patients (41% versus 28%, 
seretide versus fluticasone). Exacerbations occurred 
at much lower rates overall in this cohort (,0.5 mean 
exacerbations/patient/year in both groups), further 
Table 2 example of adult asthma self-management plan: what to 
do and when
Step Peak flow Symptoms Action
1 80%–100%  
best
intermittent/few Continue regular  
inhaled corticosteroids;  
use inhaled β-agonist  
for relief of symptoms
2 ,80%–85%  
best
waking at night  
with asthma;  
increasing  
β-agonist use
increase the dose of 
inhaled corticosteroid  
or start if not currently  
taking
3 ,60%–70%  
best
Beta-agonist use 
.2 hourly;  
increasing 
breathlessness
Start oral corticosteroids 
and contact a doctor
4 ,50% best Severe attack  
of asthma; poor  
response to  
β-agonist
Call emergency doctor  
or ambulance urgentlyJournal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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  suggesting that most of these patients had concordant 
disease appropriate for this symptom-driven type of man-
agement. Other phenotypes, however, run the potential 
risk of over- or undertreatment.
The advantage of combination therapy in being able to 
control asthma at lower doses of corticosteroids while   reducing 
the total number of inhalers has since led to its widespread 
adoption in most management guidelines. There has been 
recent concern that though LABAs improve lung function and 
symptoms in asthma, their use may be associated with more 
severe symptoms and increased mortality29,30 during severe 
exacerbations of asthma. It is not clear, however, whether the 
link between LABAs and   worsening asthma exacerbations 
is causal or rather whether the use of LABAs reflects more 
severe asthma or may reduce   adherence to corticosteroids by 
improving symptoms without   addressing underlying airway 
inflammation. Nevertheless, these concerns have led to a 
decision by the US Food and Drug Administration to issue a 
‘black box’31 warning to confine the use of LABAs to patients 
who remain poorly controlled despite inhaled corticosteroids 
and to recommend in pediatric and adolescent patients that 
LABAs should only be prescribed in a combination inhaler 
to ensure adherence to both medications.
Single maintenance and reliever therapy
Inherent in persistent asthma is the periodic need for reliever 
medication for symptoms that may invite overreliance on 
short-acting β2-agonists at the expense of reduced adherence 
to inhaled corticosteroid therapy (ICS).
Formoterol, an LABA, uniquely offers both immediate 
(within 1–3 min) and sustained bronchodilation32 equivalent 
to salbutamol, allowing its use in combination preparations to 
be used in single maintenance and reliever therapy (SMART) 
recognized by international guidelines.
Although short-acting bronchodilators provide rapid 
relief of symptoms such as dyspnea associated with 
allergen-induced bronchoconstriction, they fail to address 
the accompanying eosinophilic inflammation known to 
precede exacerbations in asthma.33 One potential advantage 
of the SMART strategy is that patients will simultane-
ously receive additional doses of inhaled corticosteroids 
alongside a bronchodilator when they use their combined 
inhaler for symptom relief. This may target anti-inflamma-
tory treatment to periods of poor control when it is most 
needed, aside from the convenience the strategy may give 
to patients.
The FACET study28 demonstrated that both budesonide 
and formoterol had complementary effects on reducing 
exacerbations in adults and provided greater improvements 
in symptoms at low doses. Pharmacologically, both budes-
onide and formoterol reduce the secretion of granulocyte-
macrophage colony-stimulating factor, counteracting the 
capacity of formoterol alone to induce interleukin-8 (IL-8) 
production, which may itself facilitate improved asthma 
control.34 Corticosteroids also promote increased expression 
of β2-receptors through gene transcription,35,36 protecting 
against the loss of LABA response, which is essential when 
used in rescue therapy.
Several studies have consequently sought to   demonstrate 
the added advantages of SMART over conventional main-
tenance therapy, though with mixed results. Exacerbations 
(the clinical endpoint of most comparison trials of SMART) 
have been significantly reduced when higher doses of ICS 
have been employed in the flexible dosing of budesonide/ 
formoterol therapy. O’Byrne et al37 showed that although 
patients on SMART averaged 50% higher mean daily ICS 
doses than patients using traditional fixed combination 
therapy with short-acting β2-agonists, they used sig-
nificantly less ICS overall than those on higher-dose ICS 
alone. SMART also conferred at least a 45% reduction in 
severe exacerbations compared with other treatment arms. 
Other studies using similar combination therapies in fixed 
doses have found similar reductions in exacerbations. 
Bousquet et al38 in a study involving 2309 patients across 
17 countries, compared the use of formoterol/budesonide 
as maintenance and reliever therapy with sustained high-
dose salmeterol/fluticasone. No significant difference in 
the primary endpoint of time to first exacerbations was 
seen, though there was a modest reduction in the total 
number of exacerbations again despite being on a lower 
dose of inhaled corticosteroid. A retrospective analysis of 
several studies of the use of SMART has raised concerns 
that this strategy fails to provide good day-to-day symptom 
control for the majority of patients39 in addition to the anti-
inflammatory mode of action being cast into doubt.40
Although not demonstrably improving asthma control 
above other combination therapies, it does allow patients 
a reduction in inhalers, which may play a helpful role in 
improving adherence,41 particularly in those who are poorly 
adherent to ICS.42
Airway inflammometry
The use of noninvasive biomarkers in monitoring airway 
inflammation has provided an alternative method to patient-
driven symptom management for the assessment and man-
agement of asthma.Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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Inflammometry43 provides a direct measure to identify 
the need for corticosteroids in relation to underlying airway 
inflammation, allowing judicious use of these agents to 
improve symptoms and reduce exacerbations and medica-
tion side effects. The use of nebulized hypertonic saline to 
induce sputum has provided a simple, safe, noninvasive airway 
  sampling technique44 to assess airway inflammation and has 
now secured a place in managing patients with chronic cough45 
and refractory asthma12,46,47 where it has shown particular ben-
efit, though its use is still mainly limited to tertiary centers.
induced sputum eosinophil counts
Healthy subjects usually have a sputum eosinophil count 
of ,1.9%, but this is commonly elevated in up to 60% of 
patients with asthma. Additionally, infiltration of the airway 
mucosa with activated eosinophils is observed in   postmortem 
examinations of patients who have died of acute severe 
asthma.48 Early studies published in the Lancet in 1958 had 
shown the importance of an airway eosinophilia in   predicting 
the clinical response to prednisolone with a reduction in 
eosinophils seen in sputum smears.49 The response to corti-
costeroids is further explained by the increased eosinophil 
apoptotic rate observed.50
A cutoff of 3% for sputum eosinophilia has been shown 
to identify individuals with corticosteroid-responsive 
asthma51 and, utilizing this, we46 successfully demonstrated 
the benefits of a management strategy directed at normal-
izing eosinophilic airway inflammation over a standard 
symptom-based management strategy. This was based on the 
hypothesis that low sputum eosinophil counts would predict 
few exacerbations.
We randomized 74 attending outpatients with moderate 
to severe asthma into treatments based on standard guidelines 
(BTS) or to a management strategy directed at maintaining 
the sputum eosinophil count at or below 3% using anti-
inflammatory therapy, both inhaled and oral. If the sputum 
eosinophil count was ,1%, irrespective of asthma control, 
anti-inflammatory treatment was reduced. If the eosinophil 
count was 1%–3%, no changes to anti-inflammatory treat-
ment were made, and if the eosinophil count was .3%, 
anti-inflammatory treatment was increased. Bronchodilator 
treatment was modified according to individual patients’ 
symptoms, rescue β2-agonists use, and peak expiratory flow 
readings compared with baseline using the same measures 
as in the standard management group (Figure 2). There were 
significantly fewer severe exacerbations in the sputum man-
agement group in contrast to the BTS management group (35 
versus 109 total exacerbations, respectively, P = 0.01) and 
fewer rescue courses of oral corticosteroids (24 versus 73, 
P = 0.008). Additionally, we demonstrated a significant 
reduction in the inhaled corticosteroid dose in those managed 
by sputum guidelines compared with baseline, in contrast 
to an increase in dose in the BTS group. This demonstrated 
that the sputum management strategy allowed appropriate 
targeting of anti-inflammatory treatment where it was most 
needed and an avoidance of inappropriately high doses in 
patients who were unlikely to benefit. Accepting that wide-
spread inflammometry using induced sputum is not available, 
this tailored approach offers significant proven benefits to 
patients with severe asthma, particularly in avoiding harmful 
unwarranted treatment.
Fraction of nitric oxide in exhaled air
Alternative noninvasive measurements of airway inflam-
mation have since been sought to offer supportive bedside 
  measures easily and readily available outside of large hos-
pitals or research centers. Against this background, with its 
  reproducibility and noninvasive nature, the measurement of 
fraction of exhaled nitric oxide (FeNO), which is elevated 
in the presence of airway inflammation, has attracted inter-
est   furthered by its relationship, albeit loose, to sputum 
  eosinophils. Although confounded by factors such as atopy52 
and respiratory viral infections,53 and widely varying agreed 
  cutoff values and confidence intervals (CIs),54,55 FeNO appears 
to be a useful screening and management tool in asthma in 
defining lower airway pathology, being rarely present in 
nonasthmatics54,56 and lowered by use of corticosteroids.57
Two main trials in adults have evaluated the use of FeNO 
in conjunction with clinical parameters to titrate inhaled 
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corticosteroid dose. Shaw et al58 recruited 128 patients 
from primary care, randomized them to two groups, and 
  evaluated them over a 1-year period. ICS was adjusted 
according to FeNO levels, where above 26 parts/billion (ppb) 
it was increased and if it was ,16 ppb or ,26 ppb on two 
  consecutive occasions, treatment was decreased.   Additional 
bronchodilator therapy was used to control symptoms. 
No significant differences were observed between the two 
  treatment arms. The FeNO management strategy resulted in 
0.33 exacerbations/patient/year (0.69) in the FeNO group 
and 0.42 (0.79) in the control group (mean difference −21%; 
95% CI: −57%–43%; P = 0.43). The study did not, however, 
have sufficient power to demonstrate a more modest effect 
on exacerbation frequency.
Smith et al56 used FeNO in managing an ICS downtitra-
tion and compared it with conventional guidelines based on 
a protocol algorithm and an FeNO cutoff of 35 ppb equiva-
lent. This also resulted in a 40% ICS dose reduction without 
change in the exacerbation frequency. Although results 
from these and other studies59 using different FeNO cutoff 
levels suggest a beneficial effect in using FeNO in managing 
asthma, it has yet been shown to improve asthma control. 
Moreover, trials in pediatric asthma populations included 
in a recent Cochrane review60 potentially resulted in higher 
doses of inhaled corticosteroids in children. Although FeNO 
has shown promise as a tool in the diagnosis and treatment 
of asthma, further studies incorporating individualized FeNO 
profiles into treatment algorithms are needed.
The recognition and management  
of nonadherence
Despite all the advances in expensive biological therapeutics, 
identifying nonadherence is of important diagnostic value in 
severe asthma. Worryingly, several studies have found that 
a significant proportion of patients with difficult asthma are 
poorly adherent to inhaled and oral corticosteroid therapy. 
Gamble et al61 found that 35% of patients collected less than 
half of their prescription, and 88% admitted poor adher-
ence with inhaled therapy after initial denial. We have also 
shown that patients with severe asthma who adhere poorly 
to inhaled corticosteroids have worse asthma control and 
higher ITU admissions.62 Not infrequently, patients also 
forget or fail to understand proper inhaler technique,63 which 
should be demonstrated at least once and perhaps on repeated 
  occasions, as adherence is learned behavior that can be 
improved with practice and reinforcement. Reasons for poor 
adherence are numerous,64,65 though strategies to prevent and 
  correct   nonadherence are difficult and there is no convincing 
  evidence for their success in asthma.66 Suggested approaches 
are to improve patient education by targeted interventions, 
and there is some evidence to support the introduction of 
asthma self-management plans as already outlined in improv-
ing adherence.67 The use of combination inhalers as single 
inhaler therapy as described above is attractive, and there is 
some evidence to suggest that this approach may increase the 
likelihood of adherence to inhaled corticosteroids,42 although 
further work is needed to confirm this. Finally, for some 
patients with particularly severe asthma who are thought to 
be nonadherent to treatment and who are at risk of near-fatal 
attacks, we and others have used short courses of intramus-
cular triamcinolone to demonstrate a good steroid response 
and exclude true corticosteroid resistance.4 Improvement in 
asthma control following systemic corticosteroids in this way 
may increase patients’ awareness of their poor asthma control 
and motivate them to start taking their treatment regularly to 
maintain improvements in their symptoms.4,68,69
Novel therapeutic options
Despite effectively reducing exacerbations, systemic cor-
ticosteroids have significant adverse effects in asthma that 
prohibit their long-term use and have driven the search for 
alternative therapies with acceptable risk-to-benefit ratios not 
achievable with commonly used immunosuppressants such 
as methotrexate, azathioprine, gold, or cyclosporine.63
Much recent work has therefore been concerned with the 
introduction of novel therapies targeting specific components 
of the anti-inflammatory pathway usually via a systemic 
approach. These include monoclonal antibodies (mAbs) tar-
geting IgE, tumor necrosis factor-alpha (TNF-α) or IL-5, and 
thermal bronchoplasty and antifungal agents. In view of their 
invasive nature, risk of adverse effects, and expense, these 
treatments are likely to have narrow, well-defined roles in 
asthma management and will usually be reserved for patients 
with difficult-to-treat asthma. The evidence supporting their 
use will now be discussed.
Anti-ige therapy
Allergens are one of the many multiple triggers in asthma,70 
and through their tendency for IgE production give rise 
to   airway inflammation, which is an important aspect of 
allergic asthma and exacerbations.
The first of the European Community Respiratory Health 
Surveys, a cross-sectional, multicenter study, identified the 
rates of atopy as defined by an elevated specific IgE to com-
mon aeroallergens as varying from 4% to 61%, depending 
on the country examined.71Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
8
Agbetile and Green
The IgE receptor FcεRI is significantly upregulated on 
eosinophils, mast cells, macrophages, and dendritic cells in 
patients with rhinitis and allergic asthma. Mast cell activation 
through IgE releases a variety of proinflammatory cytokines 
including IL-4, IL-13, and IL-5 all contributing to the inflam-
matory and bronchoconstrictive response seen in asthma.
Omalizumab, a recombinant humanized monoclonal 
antibody, is the first treatment to specifically bind IgE and 
block its effects. It targets the Fc region that attaches to the 
high-affinity receptor FcεRI, binding free IgE, significantly 
reducing circulating free IgE levels, and downregulating 
the receptor.
In a 28-week, randomized, placebo-controlled trial, 
the Investigation of Omalizumab in Severe Asthma Treat-
ment (INNOVATE) study72 demonstrated the efficacy of 
omalizumab in those with severe persistent allergic asthma 
as add-on therapy, showing significant improvements in 
quality of life across all domains and a 26% reduction in 
exacerbation rates when corrected for baseline exacerbations 
compared with placebo (P = 0.002).
Earlier studies in patients with sputum eosinophilia eluci-
dated their mechanisms of action in the depletion of IgE from 
airway tissue with marked reductions in airway eosinophilia 
as measured by sputum and bronchial biopsies.73
Patients with recurrent exacerbations appear to ben-
efit most from this treatment. A recent Cochrane review74 
concluded highly significant reductions in frequency and 
duration of exacerbations, including a 90% reduction in 
hospitalization, together with a reduction in the use of both 
inhaled steroids and rescue drugs. Compliance issues are also 
minimized with its administration as 2–4 weekly subcutane-
ous injections with the dose based on the patients’ serum total 
IgE level and body weight.
Omalizumab treatment is generally well tolerated with 
few adverse effects, although anaphylaxis attributed to its 
administration has been quoted as being between 0.1% and 
0.2% in clinical trials and postmarketing survelliance.75 
In addition, clinical trial data suggest that, numerically, 
more malignancies were reported in patients receiving 
omalizumab compared with control (0.5% versus 0.2%). 
This difference was not statistically significant, but the 
long-term risk of additional malignancies is unknown. The 
major limitation to the use of omalizumab is its cost, which 
restricts its use in patients with severe atopic uncontrolled 
asthma despite adequate doses of inhaled corticosteroids and 
LABAs who demonstrate persistent symptoms and a degree 
of airflow obstruction and who are sensitized to a perennial 
allergen. In addition, patients’ total IgE levels should be in 
the range of 30–1500 IU/mL, and some patients will have a 
total IgE greater than the maximum recommended for dos-
ing in relation to their body weight. A recent audit in our 
clinic showed that only 34 out of 251 patients with difficult-
  to-control asthma were eligible for treatment based on these 
licensing criteria.76 Furthermore, in the UK, guidance from 
the National Institute for Health and Clinical Excellence 
now limits its prescription to patients who meet the licens-
ing criteria and who have also had two or more hospital 
admissions or one admission plus two A&E attendances 
for asthma exacerbations. Using these additional criteria, 
only 6.2% of our patients were eligible for treatment with 
omalizumab. Nevertheless, if funding is available, this does 
appear to be a promising therapy for patients with severe 
atopic disease and may be particularly helpful to patients 
who have additional atopic diseases alongside asthma, such 
as severe rhinitis.77
Antitumor necrosis factor-α therapy
In patients with rheumatoid arthritis, TNF-α, with its abil-
ity to promote inflammation, is markedly increased in the 
synovial fluid, and treatment with TNF-α mAbs has resulted 
in substantial improvement in disease activity scores.78 
Both macrophage and mast cells release TNF-α in allergic 
responses via IgE-dependent mechanisms79 and can also 
induce its own production via an autocrine mechanism. The 
TNF-α axis is found to be upregulated in patients with severe 
asthma80,81 and is consequently thought to play a key role in 
the pathogenesis of inflammatory disorders. This recogni-
tion has led to trials of anti-TNF-α therapy in patients with 
asthma. Despite initially promising results, subsequent stud-
ies have not only shown a marked heterogeneous response, 
suggesting benefit to a small subgroup, but also highlighted 
concerns about its safety.
Using the most widely studied anti-TNF agent in 
asthma, etanercept, Berry et al80 demonstrated significant 
improvements in airways hyperresponsiveness and quality 
of life and reduced expression of membrane-bound TNF-α 
by peripheral blood monocytes in patients with refractory 
asthma treated for 10 weeks. Morjaria et al82 found small 
but similar significant improvements in patients’ asthma 
control questionnaire responses but failed to replicate other 
earlier findings in an unselected refractory asthma popula-
tion. The largest and longest study to date, using golimumab 
for 52 weeks and involving 231 patients, found no benefit 
compared with placebo.83
Unfortunately, anti-TNF antibody agents may increase the 
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rheumatoid arthritis,84 though larger, more carefully selected 
studies may be required before this therapy is abandoned.
Anti-iL-5 therapy
IL-5 has long been regarded as an important cytokine respon-
sible for eosinophil differentiation, maturation, migration, 
and survival. mAbs directed against this cytokine offering 
the prospect of abolishing exacerbations without entertain-
ing the significant problems associated with corticosteroid 
therapy seemed possible.
The initial enthusiasm for anti-IL-5 was, however, tam-
pered by the apparent failure of eosinophilic suppression 
through anti-IL-5 to confer clinical benefit in the asthmatic 
late response. Leckie et al85 showed that anti-IL-5 blockade 
effectively suppressed blood and sputum eosinophilia in 
the mild asthmatic cohort, but in studying airway hyper-
responsiveness as an outcome failed to appreciate that these 
measures are not closely associated with eosinophilic airway 
inflammation. This suggests that the choice of an alternative 
outcome measure may have demonstrated significant patient 
benefits. The demonstration that a sputum and bronchial 
submucosal eosinophilia occurs in eosinophilic   bronchitis, 
a condition that presents with chronic cough without   airway 
hyperresponsiveness,86 further supports this view, as did 
earlier studies demonstrating significant reductions in eosino-
philic exacerbations using management strategies that control 
airway inflammation.46
In a double-blind, placebo-controlled trial, the larg-
est to date, involving patients with refractory asthma and 
eosinophilic inflammatory phenotypes, we have shown the 
profound effect of mepolizumab on suppressing both blood 
and sputum eosinophils.87 This effect consequently reduced 
asthma exacerbations significantly, with a reduction in epi-
sodes requiring high-dose oral corticosteroids (2 versus 3.4 
exacerbations/subject/year; P = 0.02) as well as improved 
quality of life. There were no improvements in symptoms 
or forced expiratory volume in 1 second consistent with 
previous studies,88 further illustrating the disassociation 
between eosinophilic airway inflammation and day-to-day 
symptoms and lung function while confirming the increased 
risk of exacerbations seen alongside uncontrolled airway 
eosinophilia. Nair et al89 also evaluated a similar steroid-
dependant cohort involving 20 patients; 9 were treated with 
mepolizumab 750 mg administered over 5 monthly infusions 
and 11 patients received placebo. Again, the mepolizumab 
group experienced a significant decrease in asthma exac-
erbations and were able to reduce their prednisolone dose 
significantly.
Further work is ongoing with the larger multicenter study 
Dose Ranging Efficacy and Safety with Mepolizumab in 
Severe Asthma (DREAM)90 underway, but the likely role 
for this treatment will be in a selected group. Importantly, 
characterizing patients with inflammometry provides targeted 
treatment and is likely to be particularly helpful in selecting 
patients for treatment with anti-iL-5, because those patients 
with inflammation-predominant disease are particularly 
likely to benefit.
Antifungal therapy
With up to 60% of patients with asthma being atopic to 
common aeroallergens, sensitization to fungi appears to 
be an emerging phenotype conferring an increased risk of 
hospital and ITU admissions.91 Exposure to allergenic fungi 
is ubiquitous in the aerospora, which we have shown to be 
present in sputum from colonized airways of patients with 
asthma,92 further increasing the body of evidence about the 
link between fungal sensitization and severe asthma.93
Several trials in patients with allergic bronchopulmonary 
aspergillosis94 have established the role of antifungal therapy, 
but only recently have trials in asthma been undertaken. The 
Fungal Asthma Sensitization Trial (FAST)95 studied patients 
with severe asthma who were sensitized by a skin prick or 
radioallergosorbent testing to one or more fungal allergens 
and did not fulfill the criteria for allergic bronchopulmonary 
mycosis. Treatment with oral itraconazole 200 mg twice 
daily/placebo for 32 weeks resulted in clinically significant 
improvements of asthma quality of life scores as well as 
rhinitis and morning peak flows.
Interestingly, the precise mechanisms of antifungal action 
in asthma remain unknown. Although generally accepted 
to modulate the immunological response, concerns remain 
about the azole–corticosteroid interaction as seen in earlier 
trials with adrenal suppression.94 Although active against 
some species of Aspergillus, itraconazole is not active against 
all of the fungal species that the human airway is constantly 
subjected to. Its microbiological activity is further limited by 
variable absorption and need for monitoring96 in contrast to 
newer triazoles that have better oral bioavailability. Further 
trials in this interesting area are warranted.
Thermal bronchoplasty
Targeted treatment of the airway smooth muscle hypertrophy 
seen in chronic asthma, aside from other changes of airway 
remodeling including goblet cell hyperplasia, increased 
mucus secretion, and increased vascularization, has been 
made possible with a novel technique utilizing radiofrequency Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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ablation. Treatment involves delivering thermal energy 
through use of a standard bronchoscope into which a catheter 
containing an expandable basket is inserted. When extended, 
this comes into circumferential contact with the walls of tar-
geted airways, thus depleting smooth muscle mass with the 
hope of attenuating the bronchoconstrictor response.
In clinical studies, thermal bronchoplasty has been shown 
to reduce parameters of airways hyperresponsiveness and 
minimize exacerbations. The randomized, double-blind, sham-
controlled AIR 2 study97 built on earlier promising results98 
and demonstrated a clinically significant   improvement in 
asthma quality of life in up to 80% of patients over those 
treated with the sham protocol, as well as a 36%   reduction in 
exacerbations with benefits persisting at 1 year.
The benefits were overshadowed early on, however, 
with a higher rate of exacerbations in the treatment arm up 
to 6 weeks after therapy (6% more than placebo). All other 
adverse events were not significantly different. These exac-
erbations required hospital admissions and steroids, which 
may have confounded the improved asthma control seen later 
on. More important was the profound placebo effect, with 
64% of sham subjects achieving changes in Asthma Quality 
of Life Questionnaire of 0.5 or greater.
This procedure offers a novel way to reduce the expres-
sion of smooth muscle in patients not controlled with 
combinations of anti-inflammatory and bronchodilators. 
This suggests that its greatest potential is in the long-lasting 
duration of effect in contrast to other therapies, but longer 
follow-up studies are required to evaluate this.
Conclusion
Treatments for asthma are rapidly evolving with the devel-
opment of both novel pharmacological therapies and the 
establishment of new management strategies with which to 
deploy existing therapies. With these developments has come 
the recognition that previous goals of therapy can be improved 
to focus not only on preventing death and severe exacerba-
tions but also on improving day-to-day symptom control 
and quality of life. Individual treatments and management 
strategies in general are likely to be most successful where 
they offer convenience for patients and/or aid adherence. 
Many of these patient-focused strategies are readily available. 
Although sputum cell analysis had previously been limited as 
a research tool, it is gradually gaining widespread acceptance 
as an invaluable biomarker in clinical practice in concert with 
the developments in bedside inflammometry using FeNO.
Although novel biological therapies offer a useful adjunct 
for those patients who are unresponsive to conventional 
treatment, the varied responses to these agents emphasize the 
need for careful patient selection. This highlights the vital 
importance of accurate phenotyping of the asthma population 
not only to ensure that each individual patient receives the 
most appropriate therapy but also to maximize the likelihood 
of the successful development of additional new drugs.
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